11 unchanged sentences
Purchased Under
−Removed: July 1, 2024 - July 31, 2024 974 (1)
+Added: January 1, 2025 - January 31, 2025 938 (1)
— $3,502,031,203
−Removed: August 1, 2024 - August 30, 2024 856 (1)
+Added: February 1, 2025 - February 28, 2025 866 (1)
— $3,502,031,203
−Removed: September 1, 2024 - September 30, 2024 902 (1)
+Added: March 1, 2025 - March 31, 2025 2,836,890 (1)
2,836,000 $2,896,110,760
1 unchanged sentence
2,836,000 $2,896,110,760
−Removed: In addition to AbbVie shares repurchased on the open market under a publicly announced program, if any, these shares also included the shares purchased on the open market for the benefit of participants in the AbbVie Employee Stock Purchase Plan – 974 in July;
−Removed: 856 in August;
−Removed: and 902 in September.
+Added: In addition to AbbVie shares repurchased on the open market under a publicly announced program, these shares also included the shares purchased on the open market for the benefit of participants in the AbbVie Employee Stock Purchase Plan – 938 in January;
+Added: 866 in February;
+Added: and 890 in March.
These shares do not include the shares surrendered to AbbVie to satisfy minimum tax withholding obligations in connection with the vesting or exercise of stock-based awards.
(c) Director and Officer Trading Arrangements
−Removed: During the three months ended September 30, 2024, no director or officer of the company adopted, modified or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
+Added: During the three months ended March 31, 2025, no director or officer of the company adopted , modified or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
2025 Form 10-Q |
1 unchanged sentence
Exhibit Description
+Added: Form of AbbVie Inc.
+Added: Performance-Vested Restricted Stock Unit Agreement*
+Added: Form of AbbVie Inc.
+Added: Performance Share Award Agreement*
+Added: Form of AbbVie Inc.
+Added: Non-Employee Director RSU Agreement (US)*
+Added: Form of AbbVie Inc.
+Added: Non-Qualified Stock Option Agreement*
+Added: Non-Employee Directors’ Fee Plan, as amended and restated*
Certification of Chief Executive Officer Required by Rule 13a-14(a) (17 CFR 240.13a-14(a)).
5 unchanged sentences
101 The following financial statements and notes from the AbbVie Inc.
−Removed: Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, filed on November 4, 2024, formatted in iXBRL (Inline eXtensible Business Reporting Language):
+Added: Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed on May 9, 2025, formatted in iXBRL (Inline eXtensible Business Reporting Language):
(i) Condensed Consolidated Statements of Earnings;
7 unchanged sentences
_______________________________________________________________________________
+Added: * Denotes management contract or compensatory plan or arrangement required to be filed as an exhibit hereto.
2025 Form 10-Q |
2 unchanged sentences
Chief Financial Officer (Principal Financial Officer)
−Removed: November 4, 2024
2025 Form 10-Q |
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.